Women’s knowledge about pregnancy complicated by breast cancer and the attitude towards the implementation of anti-cancer therapy

Introduction and purpose: Breast cancer is the most commonly diagnosed cancer during pregnancy. Women can treat it, but pregnancy has a significant impact on the types and duration of using treatment. Purpose is to present the opinions of women about pregnancy complicated by breast cancer. Material and methods: 206 women participated in the study. We used a survey on the Internet. The average age of the respondents was 31.2. To establish whether an observed frequency distribution differs from a theoretical distribution the chi2 test of goodness-of-fit was used, to estimate relation we use the chi2 test of independence. Results: There were statistically significant differences between the number of women who believe that breast cancer is benign vs. malignant. Most often indicated as a safe method of diagnosis in pregnant women were: biopsy, mammography with lead shield, ultrasound, there was also a relationship between the place of residence and the choice of biopsy and ultrasound. A significant difference was noted between the number of women declaring an attitude forward delay vs starting treatment in pregnancy. There was a significant relationship between the pregnancy experience and the declared decision on the time of beginning of the therapy. Conclusions: The results suggest that women are aware of the malignancy of breast cancer. Many of them incorrectly differentiate the effects of this cancer in pregnant women and not pregnant. Biopsy, mammography with lead shield, ultrasound are perceived as the safest methods of diagnosis. Significantly more respondents claim that they would postpone the therapy until the end of pregnancy. Women who have never been pregnant more often declare that they would decide to postpone treatment. Key words: breast cancer; pregnancy; attitude; knowledge

Thermal transformations of Cu–Mg (Zn)–Al(Fe) hydrotalcite-like materials into metal oxide systems and their catalytic activity in selective oxidation of ammonia to dinitrogen

Layered double hydroxides (LDHs) containing $Mg^{2+}$, $Cu^{2+}$ or $Zn^{2+}$ cations in the $Me^{II}$ positions and $Al^{3+}$ and $Fe^{3+}$ in the $Me^{III}$ positions were synthesized by co- precipitation method. Detailed studies of thermal trans- formation of obtained LDHs into metal oxide systems were performed using high temperature X-ray diffraction in oxidising and reducing atmosphere, thermogravimetry coupled with mass spectrometry and temperature-pro- grammed reduction. The LDH samples calcined at 600 and 900 $^{o}\textrm{C}$ were tested in the role of catalysts for selective oxidation of ammonia into nitrogen and water vapour. It was shown that all copper congaing samples presented high catalytic activity and additionally, for the Cu–Mg–Al and Cu–Mg–Fe hydrotalcite samples calcined at 600 $^{o}\textrm{C}$ rela- tively high stability and selectivity to dinitrogen was obtained. An increase in calcination temperature to 900 $^{o}\textrm{C}$ resulted in a decrease of their catalytic activity, possibly due to formation of well-crystallised metal oxide phase which are less catalytically active in the process of selective oxidation of ammonia

Adhesion proteins--an impact on skeletal myoblast differentiation.

Formation of mammalian skeletal muscle myofibers, that takes place during embryogenesis, muscle growth or regeneration, requires precise regulation of myoblast adhesion and fusion. There are few evidences showing that adhesion proteins play important role in both processes. To follow the function of these molecules in myoblast differentiation we analysed integrin alpha3, integrin beta1, ADAM12, CD9, CD81, M-cadherin, and VCAM-1 during muscle regeneration. We showed that increase in the expression of these proteins accompanies myoblast fusion and myotube formation in vivo. We also showed that during myoblast fusion in vitro integrin alpha3 associates with integrin beta1 and ADAM12, and also CD9 and CD81, but not with M-cadherin or VCAM-1. Moreover, we documented that experimental modification in the expression of integrin alpha3 lead to the modification of myoblast fusion in vitro. Underexpression of integrin alpha3 decreased myoblasts' ability to fuse. This phenomenon was not related to the modifications in the expression of other adhesion proteins, i.e. integrin beta1, CD9, CD81, ADAM12, M-cadherin, or VCAM-1. Apparently, aberrant expression only of one partner of multiprotein adhesion complexes necessary for myoblast fusion, in this case integrin alpha3, prevents its proper function. Summarizing, we demonstrated the importance of analysed adhesion proteins in myoblast fusion both in vivo and in vitro

Downregulation of integrin alpha3 reduces the C2C12 ability to fuse with control myoblasts.

<p>A – control - myoblasts transfected with scramble siRNA-AlexaRed (red) cultured with myoblasts stained with QTracker (green), experiment+siRNA-alpha3– myoblasts cotransfected with scramble siRNA-AlexaRed (red) and siRNA-alpha3 cultured with control myoblasts stained with QTracker (green). Hybrid myotubes are yellow. Scale bars 20 µm. B –number of hybrid myotubes formed by control myoblasts transfected with scramble siRNA-AlexaRed and control myoblasts stained with QTracker (control) compared with the number of hybrid myotubes formed by myoblasts co-transfected with scramble siRNA-AlexaRed and siRNA-alpha3 and control myoblasts stained with QTracker (siRNA-alpha3) (day 11 of culture). Error bars indicate SEM, results were analyzed by Student's test and differences were considered statistically significant when p<0.05 (marked with asterisks). ** p≤0.01.</p

Downregulation of alpha3 integrin expression reduces fusion of MPCs-derived myoblasts.

<p>A - Pappenheim's staining of fusing myoblasts. B – total number of nuclei calculated at day 12 of myoblast culture. C –index of fusion analyzed at day 12 of culture in control and experimental myoblasts shown as a percentage of myotube nuclei per number of all nuclei. D - proportion of 2–4, 5–7, 8–10 and >11 nuclear myotubes per number of all myotubes, respectively. NT – control, not transfected myoblasts, TR – control myoblasts cultured in medium supplemented with transfection reagent, siRNA-cont - control myoblasts transfected with scramble siRNA, siRNA-alpha3 – myoblasts transfected with siRNA downregulating the expression of integrin alpha3. Error bars indicate SEM, results were analyzed by Kruskal-Wallis test. Kruskal-Wallis One Way Analysis of Variance showed differences between experimental groups which were considered statistically significant when p<0.05 (marked with asterisks). * p≤0.05.</p

Expression of mRNAs encoding integrin alpha3 and other adhesion proteins at 24 and 48 hours after transfection of MPCs-derived myoblasts with siRNA-alpha3. sqRT-PCR analysis.

<p>NT – control, not transfected myoblasts, siRNA-alpha3 – myoblasts transfected with siRNA downregulating the expression of integrin alpha3. Optical densities of representative bands are shown as a percentage of GAPDH band density taken as a 100%.</p

Changes in expression and localization of adhesion proteins during <i>Soleus</i> muscle regeneration.

<p>A - level of mRNAs encoding adhesion proteins analyzed by sqRT-PCR. Optical densities of representative bands are shown as a percentage of GAPDH band density taken as a 100%. B – localization of integrin alpha3 (red) in intact and in regenerating muscle at day 3, 5, 7, 14. Nuclei – blue. White arrows show degenerating myofibers. Scale bars 50 µm.C –colocalization of Pax7, MyoD, myogenin (MG) (red) with integrin alpha3 (green) in intact muscle and at day 1, 3 and 5 of regeneration (intact, d1, d3, d5 respectively). White arrows - myoblasts, pink – muscle fiber nuclei, yellow - MyoD, myogenin and integrin alpha3 negative cells. D – control staing with secondary antibodies only. Nuclei – blue. Scale bars 50 µm. E - localization of integrin beta1, ADAM12, CD9, or M-cadherin (green) at day 3 of regeneration. Nuclei – blue. Scale bars 50 µm. F – immunoblotting analysis of M-cadherin (M-cad), integrin beta1, ADAM12 (AD12), CD9 and integrin alpha3 level during muscle regeneration (days 1, 3, 7, 14).</p